Published in BMC Cancer on July 20, 2010
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One (2012) 1.05
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer (2012) 0.91
Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol (2012) 0.90
An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res (2013) 0.87
Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A. Carcinogenesis (2014) 0.85
Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion. World J Gastroenterol (2012) 0.81
Effect of survivin on tumor growth of colorectal cancer in vivo. Int J Clin Exp Pathol (2015) 0.79
Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy. Oncotarget (2016) 0.78
Sevoflurane suppresses hypoxia-induced growth and metastasis of lung cancer cells via inhibiting hypoxia-inducible factor-1α. J Anesth (2015) 0.77
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget (2016) 0.75
Functionally-interdependent shape-switching nanoparticles with controllable properties. Nucleic Acids Res (2017) 0.75
The role of apoptosis in the pathology of pancreatic cancer. Cancers (Basel) (2010) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Intrinsic tumour suppression. Nature (2004) 8.73
The role of apoptosis in cancer development and treatment response. Nat Rev Cancer (2005) 4.19
Metastasis: recent discoveries and novel treatment strategies. Lancet (2007) 3.93
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem (2004) 2.18
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer (2007) 1.44
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene (2006) 1.37
Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer (2008) 1.26
Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer (2003) 1.24
Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res (2006) 1.18
Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol (2006) 0.97
Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol (2004) 0.97
The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis (1999) 0.95
bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med (2007) 0.95
Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data. Bioinformatics (2007) 0.88
Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2. World J Gastroenterol (2004) 0.85
Introduction of a survivin gene-specific small inhibitory RNA inhibits growth of pancreatic cancer cells. Anticancer Res (2005) 0.85
Bcl-XL protein levels determine apoptotic index in pancreatic carcinoma. Pancreas (2005) 0.84
Concerted deregulations of multiple apoptosis-controlling genes in pancreatic carcinoma cells. Ann N Y Acad Sci (2003) 0.82
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia (2005) 3.16
DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem (2007) 2.65
Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem (2009) 2.57
Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One (2008) 2.46
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res (2007) 2.21
CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res (2003) 2.15
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med (2009) 2.12
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia (2004) 2.08
Neuroendocrine tumors of the pancreas. Oncologist (2009) 1.91
Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene (2005) 1.89
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A (2013) 1.88
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol (2002) 1.85
Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int (2008) 1.83
Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. Ann Surg (2007) 1.79
Polypyrimidine tract-binding protein promotes insulin secretory granule biogenesis. Nat Cell Biol (2004) 1.79
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res (2006) 1.66
The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol (2009) 1.62
ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate (2003) 1.54
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol (2005) 1.51
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate (2004) 1.37
Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest (2004) 1.35
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med (2008) 1.33
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol (2006) 1.31
Quantitative perfusion analysis of transabdominal contrast-enhanced ultrasonography of pancreatic masses and carcinomas. Gastroenterology (2009) 1.29
Value of a protective stoma in low anterior resections for rectal cancer. Dis Colon Rectum (2002) 1.24
Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res (2005) 1.23
Pancreatic acinar cell carcinoma: a multi-institutional study. J Gastrointest Surg (2009) 1.23
High-resolution analysis of chromosomal imbalances using the Affymetrix 10K SNP genotyping chip. Genomics (2005) 1.21
ICA512 signaling enhances pancreatic beta-cell proliferation by regulating cyclins D through STATs. Proc Natl Acad Sci U S A (2008) 1.20
Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics (2011) 1.19
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol (2008) 1.19
Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch (2003) 1.18
CDKN2A germline mutations in familial pancreatic cancer. Ann Surg (2002) 1.18
A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer (2006) 1.16
Evaluation of the International Study Group of Pancreatic Surgery definition of post-pancreatectomy hemorrhage in a high-volume center. Surgery (2011) 1.14
cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in beta cells. Cell Metab (2006) 1.14
Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol (2005) 1.10
PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest (2010) 1.09
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Int J Surg (2013) 1.07
Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy. World J Surg Oncol (2009) 1.07
Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS One (2010) 1.07
Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors. Mol Cancer (2007) 1.06
Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist (2010) 1.06
An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med (Berl) (2009) 1.05
Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res (2006) 1.05
Molecular profiles and clinical outcome of stage UICC II colon cancer patients. Int J Colorectal Dis (2011) 1.05
DNA microarray analysis of pancreatic malignancies. Pancreatology (2004) 1.05
Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III. Int J Cancer (2006) 1.04
Solid pseudopapillary neoplasms of the pancreas: a multi-institutional study of 21 patients. J Surg Res (2009) 1.04
Prevalence of familial pancreatic cancer in Germany. Int J Cancer (2004) 1.02
Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology (2004) 1.01
No evidence for involvement of beta-catenin and APC in urothelial carcinomas. Int J Oncol (2002) 1.01
Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med (2008) 1.01
Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. J Surg Res (2011) 1.01
Systematic isolation of genes differentially expressed in normal and cancerous tissue of the pancreas. Pancreatology (2003) 1.00
Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. BMC Surg (2013) 0.99
Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg (2008) 0.97
Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg (2013) 0.97
Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology (2005) 0.97
Identification of candidate tumor-suppressor genes in 6q27 by combined deletion mapping and electronic expression profiling in lymphoid neoplasms. Genes Chromosomes Cancer (2003) 0.96
Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. J Surg Res (2009) 0.96